The COVID-19 Early Treatment Fund (CETF), which is administered by Rockefeller Philanthropy Advisors, a 501(c)(3) organization created to ensure the rapid and successful completion of outpatient clinical trials of existing drugs that lead to effective early treatments for COVID-19, today announced the results of a recently funded outpatient clinical trial at Washington University in St. Louis that examined the viability of fluvoxamine in patients with mild COVID-19.
Yahoo Finance- Tech Entrepreneur Seeks COVID-19 Treatment Using Existing Drugs
July 28, 2020
CETF Founder Steve Kirsch discusses why we can't wait for a COVID-19 vaccine, the importance of researching existing drugs now, and our work to raise funds for outpatient trials to identify effective treatments ASAP.
CETF and Steve Kirsch featured in Inside Philanthropy
June 4, 2020
Silicon Valley entrepreneur and philanthropist Steve Kirsch says a key research avenue is being ignored: the identification of a drug or drugs to prevent progression into serious illness, hospitalization or death in newly infected patients.
Dr. Prasanna Jagannathan Interview on NBC Bay Area
May 12, 2020
If you have COVID-19, Stanford Health Care may be able to help you right away. Stanford is looking for volunteers to take part in a new trial, and it wants to treat patients almost immediately after testing positive. Dr. Prasanna Jagannathan talks with Raj Mathai about the trial and the treatment.
A new clinical trial at Stanford University is part of an emerging movement to find COVID-19 medicines that can be given almost immediately after infection, before the virus gains a firm foothold in the body.
Oops! Something went wrong while submitting the form.
COVID-19 Early Treatment Fund (CETF)
The COVID-19 Early Treatment Fund (CETF) is administered by Rockefeller Philanthropy Advisors, a 501(c)(3) public charity (EIN: 13-3615533). All donations to CETF are tax deductible and go exclusively towards funding outpatient trials.